Keywords : biosimilars, generics, prasugrel, losartan
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, s...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: January 2011
- Report price: $ 341
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Ranbaxy is India’s leading pharmaceutical company, one of only a handful so far to achieve international prominence. Manufacturing is conducted mainly in India, but also in other countries.
In June 2008, in a surprise move, Daiichi Sankyo announced plans to acquire Ranbaxy in a deal which valued Ranbaxy at US$8.5 billion. The acquisition was completed in October 2008. As a result, the two firms are undergoing a reorganisation process to combine their strengths.
In 2004, revenues broke the US$1 billion mark for the first time. In 2009, Ranbaxy recorded total consolidated revenues worth Rs80,837.0 million (US$1,670.9 million). Profit after tax reached Rs2,964.9 million (US$61.3 million), compared to a loss of Rs9,512.1 million in 2008.
The company claims its long term aim is to move away from generics and into original drug research. This is partly spurred by the tightening of India’s patent laws which began in 2005. The firm is undertaking research into a new anti-malarial product.
Generic Drug Industry in Europe
Table of Contents
Executive Summary 1
Introduction 2
Acquisition by Daiichi Sankyo 2
FDA action 2
Products 3
New Drug Discovery research 4
Pharmaceutical Research (dosage forms) 5
Chemical Research (active pharmaceutical ingredients) 5
Ranbaxy Laboratories: international regulatory filings and approvals, 2009 5
Ranbaxy ANDA Approvals, January 2002 –September 2010 6
Ohm Laboratories ANDA Approvals, January 2002 – September 2010 8
Antiretrovirals 8
Recent product approvals 9
Prasugrel (India) 9
Atorvastatin (South Africa) 9
Valacyclovir (US) 9
Atorvastatin (Canada) 10
Ranbaxy to launch olmesartan medoxomil in six African countries 10
Raloxifien (Romania) 10
Calcitriol (authorised generic, US) 11
Glycopyrrolate (US) 11
Sumatriptan (US) 11
Losartan (Malaysia) 11
Ropinirole (Canada) 11
Simvastatin (Canada) 11
Amlodipine (Canada) 12
Financial results 13
Latest Quarter Results – Q310 13
Ranbaxy Laboratories: consolidated quarterly results, in Rs millions 13
Ranbaxy Laboratories: consolidated quarterly results, in US$ millions 13
Latest Fiscal Year Results – FY2009 14
Ranbaxy Laboratories: consolidated fiscal year results, in Rs millions 14
Ranbaxy Laboratories: consolidated fiscal year results, in US$ millions 14
Ranbaxy Laboratories: consolidated fiscal year sales by region, in Rs millions 15
Ranbaxy Laboratories: consolidated fiscal year sales by region, in US$ millions 15
Major developments 15
Ranbaxy sets up South African manufacturing facility 15
Daiichi Sankyo to use Ranbaxy to market levofloxacin product in Romania, South Africa 16
Ranbaxy's New Drug Discovery Research arm transferred to Daiichi Sankyo 16
Daiichi Sankyo to launch innovator products in Mexico through Ranbaxy subsidiary 16
Ohm Laboratories receives FDA Warning Letter 17
Ranbaxy and Nippon Chemiphar dissolve Japanese joint venture 17
Ranbaxy relocates European headquarters 17
South African Competition Commission places conditions on Aspen / GlaxoSmithKline agreement 18
Ranbaxy gains Japanese GMP approval for non-sterile plant 18
Daiichi acquires Ranbaxy 19
Mergers, acquisitions and agreements 20
Ranbaxy and Pfenex announce biosimilar development agreement 20
Syntropharma signs agreement with Ranbaxy 21
Ranbaxy acquires product rights and facility from Biovel 21
Ranbaxy transfers shareholding in Ranbaxy (Guangzhou China) 21
Litigation 22
Companies settle pioglitazone challenges 22
Generic Drug in Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: European Generic Medicines Association (EGA), IMS Health, European Federation of Pharmaceutical Indu
- Industries : Generic Drug
- Countries : United Kingdom, Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2005 To 2021
By Business Monitor International
Source: European Generic Medicines Association (EGA), IMS Health, European Federation of Pharmaceutical Indu
- Industries : Generic Drug
- Countries : Spain, Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2007 To 2021
By Business Monitor International
Source: European Generics Association (EGA), European Federation of Pharmaceutical Industries and Associatio
- Industries : Generic Drug
- Countries : France, Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, IMS Health, Association of European Self-Medication Industry (AESGP), European Federation
- Industries : Generic Drug
- Countries : Portugal, Europe
- $ 250
- Industry data
- January 2013
Yearly, From 2004 To 2021
By Business Monitor International
Source: European Generic Medicines Association (EGA), IMS Health, European Federation of Pharmaceutical Indu
- Industries : Generic Drug
- Countries : Spain, Europe
- Publication date: January 2011
- Report price: $ 341
